Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial |
| |
| Authors: | Andrea Z LaCroix Ellen W Freeman Joseph Larson Janet S Carpenter Hadine Joffe Susan D Reed Katherine M Newton Rebecca A Seguin Barbara Sternfeld Lee Cohen Kristine E Ensrud |
| |
| Institution: | 1. Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109-1024, USA;2. Department of Obstetrics & Gynecology, University of Pennsylvania School of Medicine, 3701 Market Street, Philadelphia, PA 19104-5509, USA;3. Department of Psychiatry, University of Pennsylvania School of Medicine, 3701 Market Street, Philadelphia, PA 19104-5509, USA;4. School of Nursing, Indiana University, 1111 Middle Drive, Indianapolis, IN 46202-5243, USA;5. Massachusetts General Hospital CWMH, 185 Cambridge Street, Boston, MA 02114-2790, USA;6. Group Health Research Institute, 1730 Minor Avenue, Seattle, WA 98101-1466, USA;g Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612-2304, USA;h Department of Medicine, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA;i Division of Epidemiology & Community Health, University of Minnesota, 1300 South Second Street, Minneapolis, MN 55415-2070, USA;j Division of Nutritional Sciences, Cornell University, Savage Hall, Room 410, Ithaca, NY 14853, USA |
| |
| Abstract: | ObjectiveTo evaluate the effects of escitalopram 10–20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes.Study designA double-blind, placebo-controlled randomized trial of escitalopram 10–20 mg/day vs. identical placebo was conducted among 205 women ages 40–62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010.Main outcome measuresThe primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG).ResultsOutcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of −0.41; 95% confidence interval (CI) −0.71 to −0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference −0.75; 95% CI −1.28 to −0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of −0.33; 95% CI −0.81 to 0.15; p = 0.045).ConclusionsTreatment with escitalopram 10–20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain. |
| |
| Keywords: | Antidepressants Escitalopram Menopausal quality of life Randomized controlled trial Vasomotor symptoms |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
